Searched for: in-biosketch:yes
person:ehrlib03
Neutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis
Ogino, Noriyoshi; Leite, M Fatima; Guerra, Mateus T; Kruglov, Emma; Asashima, Hiromitsu; Hafler, David A; Ito, Takeshi; Pereira, João P; Peiffer, Brandon J; Sun, Zhaoli; Ehrlich, Barbara E; Nathanson, Michael H
Neutrophil infiltration occurs in a variety of liver diseases, but it is unclear how neutrophils and hepatocytes interact. Neutrophils generally use granule proteases to digest phagocytosed bacteria and foreign substances or neutralize them in neutrophil extracellular traps. In certain pathological states, granule proteases play a destructive role against the host as well. More recently, nondestructive actions of neutrophil granule proteins have been reported, such as modulation of tissue remodeling and metabolism. Here, we report a completely different mechanism by which neutrophils act nondestructively, by inserting granules directly into hepatocytes. Specifically, elastase-containing granules were transferred to hepatocytes where elastase selectively degraded intracellular calcium channels to reduce cell proliferation without cytotoxicity. In response, hepatocytes increased expression of Serpin E2 and A3, which inhibited elastase activity. Elastase insertion was seen in patient specimens of alcohol-associated hepatitis, and the relationship between elastase-mediated ITPR2 degradation and reduced cell proliferation was confirmed in mouse models. Moreover, neutrophils from patients with alcohol-associated hepatitis were more prone to degranulation and more potent in reducing calcium channel expression than neutrophils from healthy individuals. This nondestructive and reversible action on hepatocytes defines a previously unrecognized role for neutrophils in the transient regulation of epithelial calcium signaling mechanisms.
PMCID:11324315
PMID: 38916955
ISSN: 1558-8238
CID: 5695662
Location, location, and activation of a channel by calcium
Kuo, Ivana Y; Ehrlich, Barbara E
PMCID:9618095
PMID: 36215521
ISSN: 1091-6490
CID: 5351932
Boosting ER-mitochondria calcium transfer to treat Wolfram syndrome
Fischer, Tom T; Nguyen, Lien D; Ehrlich, Barbara E
Wolfram syndrome is a rare genetic disorder characterized by endocrine dysfunction and progressive neurodegeneration. By targeting intracellular calcium dysregulations, a sigma-1 receptor agonist rescued neurological deficits in preclinical models of Wolfram syndrome.
PMID: 35366518
ISSN: 1532-1991
CID: 5206132
BOK controls apoptosis by Ca2+ transfer through ER-mitochondrial contact sites
Carpio, Marcos A; Means, Robert E; Brill, Allison L; Sainz, Alva; Ehrlich, Barbara E; Katz, Samuel G
Calcium transfer from the endoplasmic reticulum (ER) to mitochondria is a critical contributor to apoptosis. B cell lymphoma 2 (BCL-2) ovarian killer (BOK) localizes to the ER and binds the inositol 1,4,5-trisphosophate receptor (IP3R). Here, we show that BOK is necessary for baseline mitochondrial calcium levels and stimulus-induced calcium transfer from the ER to the mitochondria. Murine embryonic fibroblasts deficient for BOKÂ have decreased proximity of the ER to the mitochondria and altered protein composition of mitochondria-associated membranes (MAMs), which form essential calcium microdomains. Rescue of the ER-mitochondrial juxtaposition with drug-inducible interorganelle linkers reveals a kinetic disruption, which when overcome in Bok-/- cells is still insufficient to rescue thapsigargin-induced calcium transfer and apoptosis. Likewise, a BOK mutant unable to interact with IP3R restores ER-mitochondrial proximity, but not ER-mitochondrial calcium transfer, MAM protein composition, or apoptosis. This work identifies the dynamic coordination of ER-mitochondrial contact by BOK as an important control point for apoptosis.
PMCID:7995216
PMID: 33691099
ISSN: 2211-1247
CID: 4953702
Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis
Ibrahim, Eiman Y; Domenicano, Ilaria; Nyhan, Kate; Elfil, Mohamed; Mougalian, Sarah S; Cartmel, Brenda; Ehrlich, Barbara E
PMCID:8121254
PMID: 33996556
ISSN: 2234-943x
CID: 4953712
Pharmacological rescue of cognitive function in a mouse model of chemobrain
Nguyen, Lien D; Fischer, Tom T; Ehrlich, Barbara E
BACKGROUND:After chemotherapy, many cancer survivors suffer from long-lasting cognitive impairment, colloquially known as "chemobrain." However, the trajectories of cognitive changes and the underlying mechanisms remain unclear. We previously established paclitaxel-induced inositol trisphosphate receptor (InsP3R)-dependent calcium oscillations as a mechanism for peripheral neuropathy, which was prevented by lithium pretreatment. Here, we investigated if a similar mechanism also underlay paclitaxel-induced chemobrain. METHOD/METHODS:Mice were injected with 4 doses of 20 mg/kg paclitaxel every other day to induced cognitive impairment. Memory acquisition was assessed with the displaced object recognition test. The morphology of neurons in the prefrontal cortex and the hippocampus was analyzed using Golgi-Cox staining, followed by Sholl analyses. Changes in protein expression were measured by Western blot. RESULTS:Mice receiving paclitaxel showed impaired short-term spatial memory acquisition both acutely 5 days post injection and chronically 23 days post injection. Dendritic length and complexity were reduced in the hippocampus and the prefrontal cortex after paclitaxel injection. Concurrently, the expression of protein kinase C α (PKCα), an effector in the InsP3R pathway, was increased. Treatment with lithium before or shortly after paclitaxel injection rescued the behavioral, cellular, and molecular deficits observed. Similarly, memory and morphological deficits could be rescued by pretreatment with chelerythrine, a PKC inhibitor. CONCLUSION/CONCLUSIONS:We establish the InsP3R calcium pathway and impaired neuronal morphology as mechanisms for paclitaxel-induced cognitive impairment. Our findings suggest lithium and PKC inhibitors as candidate agents for preventing chemotherapy-induced cognitive impairment.
PMCID:8235868
PMID: 34174909
ISSN: 1750-1326
CID: 4953722
Comprehensive somatosensory and neurological phenotyping of NCS1 knockout mice
Nguyen, Lien D; Nolte, Luca G; Tan, Winston J T; Giuvelis, Denise; Santos-Sacchi, Joseph; Bilsky, Edward; Ehrlich, Barbara E
Neuronal calcium sensor 1 (NCS1) regulates a wide range of cellular functions throughout the mammalian nervous systems. Altered NCS1 expression is associated with neurodevelopmental and neurodegenerative diseases. Previous studies focused on affective and cognitive behaviors in NCS1 knockout (KO) mice, but little is known about the physiological and pathological states associated with the loss of NCS1 in the peripheral nervous system. We previously reported that NCS1 expression was reduced following paclitaxel-induced peripheral neuropathy. Here, we comprehensively investigated the phenotypes of NCS1-KO mice through a battery of behavioral tests examining both central and peripheral nervous systems. Generally, only mild differences were observed in thermal sensation and memory acquisition between NCS1-WT and -KO male mice, but not in female mice. No differences were observed in motor performance, affective behaviors, and hearing in both sexes. These results suggest that NCS1 plays a modulatory role in sensory perceptions and cognition, particularly in male mice. NCS1 has been proposed as a pharmacological target for various diseases. Therefore, the sex-specific effects of NCS1 loss may be of clinical interest. As we examined a constitutive KO model, future studies focusing on various conditional KO models will further elucidate the precise physiological significance of NCS1.
PMCID:7840744
PMID: 33504822
ISSN: 2045-2322
CID: 4953692
Functional Interaction Between TRPV4 And NCS1 and the Effects of Paclitaxel
Sanchez, Julio C; Ehrlich, Barbara E
Neuronal calcium sensor 1 (NCS1), a calcium-binding protein, and transient receptor potential V4 (TRPV4), a plasma membrane calcium channel, are fundamental in the regulation of calcium homeostasis. The interactions of these proteins and their regulation by paclitaxel (PTX) were investigated using biochemical, pharmacological, and electrophysiological approaches in both a breast cancer epithelial cell model and a neuronal model. TRPV4 and NCS1 reciprocally immunoprecipitated each other, suggesting that they comprise a signaling complex. The functional consequence of this physical association was that TRPV4 currents increased with increased NCS1 expression. Calcium fluxes through TRPV4 correlated with the magnitude of TRPV4 currents and these calcium fluxes depended on NCS1 expression levels. Exposure to PTX amplified the acute effects of TRPV4 expression, currents, and calcium fluxes, but decreased the expression of NCS1. These findings augment the understanding of the properties of TRPV4, the role of NCS1 in the regulation of TRPV4, and the cellular mechanisms of PTX-induced neuropathy. Significance StatementTRPV4 and NCS1 physically and functionally interact. Increased expression of NCS1 enhances TRPV4 dependent currents, which are further amplified by treatment with the chemotherapeutic drug, paclitaxel, an effect associated with adverse effects of chemotherapy, including neuropathy.
PMID: 34321341
ISSN: 1521-0111
CID: 4953732
Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases
Nguyen, Lien D; Ehrlich, Barbara E
Chemotherapy is a life-saving treatment for cancer patients, but also causes long-term cognitive impairment, or "chemobrain", in survivors. However, several challenges, including imprecise diagnosis criteria, multiple confounding factors, and unclear and heterogeneous molecular mechanisms, impede effective investigation of preventions and treatments for chemobrain. With the rapid increase in the number of cancer survivors, chemobrain is an urgent but unmet clinical need. Here, we leverage the extensive knowledge in various fields of neuroscience to gain insights into the mechanisms for chemobrain. We start by outlining why the post-mitotic adult brain is particularly vulnerable to chemotherapy. Next, through drawing comparisons with normal aging, Alzheimer's disease, and traumatic brain injury, we identify universal cellular mechanisms that may underlie the cognitive deficits in chemobrain. We further identify existing neurological drugs targeting these cellular mechanisms that can be repurposed as treatments for chemobrain, some of which were already shown to be effective in animal models. Finally, we briefly describe future steps to further advance our understanding of chemobrain and facilitate the development of effective preventions and treatments.
PMCID:7278555
PMID: 32346964
ISSN: 1757-4684
CID: 4953652
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry, Rachel J; Zhang, Dongyan; Guerra, Mateus T; Brill, Allison L; Goedeke, Leigh; Nasiri, Ali R; Rabin-Court, Aviva; Wang, Yongliang; Peng, Liang; Dufour, Sylvie; Zhang, Ye; Zhang, Xian-Man; Butrico, Gina M; Toussaint, Keshia; Nozaki, Yuichi; Cline, Gary W; Petersen, Kitt Falk; Nathanson, Michael H; Ehrlich, Barbara E; Shulman, Gerald I
Although it is well-established that reductions in the ratio of insulin to glucagon in the portal vein have a major role in the dysregulation of hepatic glucose metabolism in type-2 diabetes1-3, the mechanisms by which glucagon affects hepatic glucose production and mitochondrial oxidation are poorly understood. Here we show that glucagon stimulates hepatic gluconeogenesis by increasing the activity of hepatic adipose triglyceride lipase, intrahepatic lipolysis, hepatic acetyl-CoA content and pyruvate carboxylase flux, while also increasing mitochondrial fat oxidation-all of which are mediated by stimulation of the inositol triphosphate receptor 1 (INSP3R1). In rats and mice, chronic physiological increases in plasma glucagon concentrations increased mitochondrial oxidation of fat in the liver and reversed diet-induced hepatic steatosis and insulin resistance. However, these effects of chronic glucagon treatment-reversing hepatic steatosis and glucose intolerance-were abrogated in Insp3r1 (also known as Itpr1)-knockout mice. These results provide insights into glucagon biology and suggest that INSP3R1 may represent a target for therapies that aim to reverse nonalcoholic fatty liver disease and type-2 diabetes.
PMCID:7101062
PMID: 32132708
ISSN: 1476-4687
CID: 4953632